---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-112483"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2021-09-02T23:59:59+00:00"
generated_at: "2026-06-29T06:10:12.380003+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Rhythm Pharma CMO resigns; new CMO appointed; updated Phase 3 data on setmelanotide

## Summary
- Dr. Murray Stewart resigns as CMO effective Sept 10, 2021; will serve as Senior Medical Advisor for up to one year at $12,000/month.
- Linda Shapiro Manning, M.D., Ph.D., appointed as new CMO effective Sept 10; previously SVP Clinical.
- Updated slide presentation includes new BMI reduction data from Phase 3 Bardet-Biedl syndrome trial and EMANATE powering assumptions.
- Stewart's vested options remain exercisable 3 months post-consulting; unvested options forfeited; RSUs continue vesting.
- Stewart eligible for prorated 2021 annual bonus based on employment and part-time consulting.

## SEC filing metadata
- accession: 0001104659-21-112483
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2021-09-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 5.02, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000110465921112483/0001104659-21-112483-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000110465921112483/tm2126899d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-112483
- JSON: https://secwatch.observer/filing/0001104659-21-112483.json
- Plain text: https://secwatch.observer/filing/0001104659-21-112483.txt

## Key facts
- Executive change
  Linda Shapiro Manning was appointed as Chief Medical Officer at RHYTHM PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: The Board has appointed Linda Shapiro Manning, M.D., Ph.D., currently Senior Vice President, Clinical of the Company, to succeed Dr. Stewart as Chief Medical Officer as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649904/000110465921112483/0001104659-21-112483-index.htm
- Executive change
  Murray Stewart resigned as Chief Medical Officer at RHYTHM PHARMACEUTICALS, INC..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On August 31, 2021, Murray Stewart, D.M., F.R.C.P. notified Rhythm Pharmaceuticals, Inc. (the “Company”) of his resignation as Chief Medical Officer, effective as of September 10, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649904/000110465921112483/0001104659-21-112483-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.